Global Opportunities Fund
Overview
The Strategy typically invests opportunistically in both U.S. and foreign stocks.
Morningstar Overall Rating
Class A shares rated 5 stars overall by Morningstar among 118 World Small/Mid Stock funds for the 3-, 5-, and 10 year period ended 11/30/2017 based on risk-adjusted performance.
- Inception Date
- October 22, 1990
- Investment Style
- Global Opportunity
- Fund Index
- MSCI ACWI
- CUSIP
- 683943104
- NAV
- (as of 12/15/2017)
- $66.96
- Total Assets
- (as of 11/30/2017)
- $6.91 BN
- Gross Expense Ratio
- (as of 11/30/2017)
- 1.17%
- Net Expense Ratio
- (as of 11/30/2017)
- 1.17%
Performance
AVERAGE ANNUAL TOTAL RETURNS
CUMULATIVE RETURNS
CALENDAR YEAR RETURNS
CAPITAL GAINS DISTRIBUTIONS
as of 09/30/2017
| CUMULATIVE | ANNUALIZED | |||||
|---|---|---|---|---|---|---|
| YTD AS OF 2017-09-30 | 1 YR | 3 YR | 5 YR | 10 YR | SINCE INCEPTION | |
| 33.45% | 30.48% | 20.03% | 17.81% | 9.10% | 12.22% | |
| 17.25% | 18.65% | 7.43% | 10.20% | 3.88% | - | |
Gross Expense Ratio: 1.17% | Net Expense Ratio: 1.17%
The performance data quoted represents past performance, which does not guarantee future results. The investment return and principal value of an investment in the Fund will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Current performance and expense ratios may be lower or higher than the data quoted. Fund returns include changes in share price, reinvested distributions, and a 5.75% maximum sales charge where indicated. Returns do not consider capital gains or income taxes on an individual's investment.
Portfolio
Top Issuers
(41.2% of assets as of 11/30/2017)
Nektar Therapeutics11.4%
Advanced Micro Devices3.2%
Coherent, Inc.3.0%
Nintendo Co. Ltd.2.4%
EXACT Sciences Corp.2.2%
Genmab A/S1.7%
Applied Materials, Inc.1.5%
Slm Solutions Group AG1.5%
H. Lundbeck AS1.5%
Rite Aid Corp.1.5%
SuperGroup plc1.2%
Novozymes AS1.2%
Boeing Co.1.2%
Cognex Corporation1.2%
MorphoSys AG1.2%
Ci:z Holdings Co. Ltd.1.1%
PTC, Inc.1.1%
Align Technology, Inc.1.1%
M3, Inc.1.0%
Nevro Corp.1.0%
Portfolio Holdings Breakdown
COUNTRY 4
DEVELOPED MARKETS 4
EMERGING MARKETS 4
EQUITY SECTOR 4
INDUSTRY 4
ASSET ALLOCATION 4
MARKET CAP 5
UNITED STATES
37.2%
UNITED KINGDOM
11.2%
GERMANY
8.4%
JAPAN
7.3%
DENMARK
5.7%
FRANCE
4.8%
ITALY
2.9%
SPAIN
2.5%
BELGIUM
1.6%
ISRAEL
0.8%
CANADA
0.6%
NORWAY
0.6%
SWEDEN
0.6%
FINLAND
0.6%
PORTUGAL
0.4%
CHINA
0.4%
NEW ZEALAND
0.4%
ARGENTINA
0.2%
Analytics
(As of 11/30/2017)
MORNINGSTAR 11/30/2017 (BASED ON RISK ADJUSTED PERFORMANCE)
Overall Rating
Number of Funds
118
Category
World Small/Mid Stock
PERFORMANCE STATISTICS
3Y
5Y
Alpha
13.29
9.77
Beta
1.12
1.04
Information Ratio
1.21
0.91
R-Squared
47.35
42.66
Sharpe Ratio
1.29
1.32
Standard Deviation
17.19
15.81
Upside Capture
163.46
138.28
Downside Capture
79.64
76.73
Sortino Ratio
0.67
0.67
Tracking Error
12.51
11.96
DIVIDENDS
Est. Frequency
Annual
Last Pay Date
12/7/2017
Per Share ($)
$0.0000
12-Month Distribution ($)
$0.1288
PORTFOLIO CHARACTERISTICS
FUND
FUND INDEX
Average Market Cap (weighted)
$12.70 B
$128.80 B
Median Market Cap (weighted)
$7.40 B
$54.70 B
P/E Ratio (NTM)
37.59
16.44
P/E Ratio (LTM)
28.15
19.31
Price/Book
5.00
2.35
Return on Equity
11.35%
14.54%
EPS Growth Rate 3Y
12.49%
6.00%
EPS Growth Rate 5Y
4.71%
7.20%
Sales Growth Rate 3Y
6.94%
-
Sales Growth Rate 5Y
8.59%
-
Turnover Ratio
18.00%
-
DISTRIBUTION SOURCES
Net Income
0.00%
Net Profit from Sale
100.00%
Other Capital Sources
0.00%
Insights
Documents
| Annual Report | Add to Cart | Download PDF |
| Commentary | Add to Cart | Download PDF |
| Fact Sheet | Add to Cart | Download PDF |
| Prospectus | Add to Cart | Download PDF |
| SAI | Add to Cart | Download PDF |
| Sales Charge & Commission Guide | Add to Cart | Download PDF |
| Semi-Annual Report | Add to Cart | Download PDF |
| Summary Prospectus | Add to Cart | Download PDF |
- 1. Special Risks: Foreign investments may be volatile and involve additional expenses and special risks, including currency fluctuations, foreign taxes, regulatory and geopolitical risks. Emerging and developing market investments may be especially volatile. Eurozone investments may be subject to volatility and liquidity issues. Investments in securities of growth companies may be volatile. Mid-sized company stock is typically more volatile than that of larger company stock. It may take a substantial period of time to realize a gain on an investment in a mid-sized company, if any gain is realized at all. Fixed income investing entails credit and interest rate risks. When interest rates rise, bond prices generally fall, and the Fund’s share prices can fall. Below-investment-grade (“high yield” or "junk") bonds are more at risk of default and are subject to liquidity risk. Diversification does not guarantee profit or protect against loss.
- 2. The net expense ratio (where applicable) also takes into account contractual fee waivers and/or expense reimbursements without which performance would have been less. These undertakings may not be amended or withdrawn for one year from the date of the current prospectus, unless approved by the Board.
- 3. Access index definitions.
- 4. Holdings are subject to change, and are dollar weighted based on total net assets. Negative weightings may result from the use of leverage. Leverage involves the use of various financial instruments or borrowed capital in an attempt to increase investment return. Leverage risks include potential for higher volatility, greater decline of the fund's net asset value and fluctuations of dividends and distributions paid by the fund.
- 5. Holdings are subject to change, are dollar-weighted based on assets, and may not reflect the use of leverage in the Fund. Market Cap breakdown is calculated using Morningstar's methodology and those capitalization standards may not align with those in the Fund’s prospectus.
No comments:
Post a Comment